Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden
Objective To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT).Design Retrospective analysis of serial cross-sectional screening study.Setting Population-based health e...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/6/e062172.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586972876505088 |
|---|---|
| author | Patrik Wennberg Mattias Brunström Anna Rosén Julia Otten Andreas Stomby Simon Vallin |
| author_facet | Patrik Wennberg Mattias Brunström Anna Rosén Julia Otten Andreas Stomby Simon Vallin |
| author_sort | Patrik Wennberg |
| collection | DOAJ |
| description | Objective To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT).Design Retrospective analysis of serial cross-sectional screening study.Setting Population-based health examinations within primary care in Västerbotten County, Sweden.Participants Individuals aged 40- 50 and 60 years with participation from 1985 to 2017. Those with previously diagnosed diabetes and FPG≥7 mmol/L were excluded.Primary and secondary outcome measures Prevalence of hyperglycaemia on the OGTT (IGT and T2D defined as 2-hour postload capillary plasma glucose of 8.9–12.1 mmol/L and ≥12.2 mmol/L, respectively). Analyses were further stratified by age, sex and risk factor burden to identify groups at high or low risk of IGT and T2D on testing. The numbers needed to screen (NNS) to prevent one case of T2D through detection and treatment of IGT was estimated, combining prevalence numbers with average progression rates and intervention effects from previous meta-analyses.Results The prevalence of IGT ranged from 0.9% (95% CI 0.7% to 1.1%) to 29.6% (95% CI 27.4% to 31.7%), and the prevalence of T2D ranged from 0.06% (95% CI 0.02% to 0.11%) to 7.0% (95% CI 5.9% to 8.3%), depending strongly on age, sex and risk factor burden. The estimated NNS to prevent one case of T2D through detection and lifestyle treatment of IGT ranged from 1332 among 40-year-old men without risk factors, to 39 among 60-year-old women with all risk factors combined.Conclusions The prevalence of hyperglycaemia on OGTT is highly dependent on age, sex and risk factor burden; OGTT should be applied selectively to high-risk groups to avoid unnecessary testing in the general population. |
| format | Article |
| id | doaj-art-fb111b0a3b44465a87d450fd975db741 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-fb111b0a3b44465a87d450fd975db7412025-01-24T19:45:10ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2022-062172Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, SwedenPatrik Wennberg0Mattias Brunström1Anna Rosén2Julia Otten3Andreas Stomby4Simon Vallin520 Family Medicine, Department of Public Health and Clinical Medicine, Umea University, Umea, SwedenDepartment of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå, Sweden4 Diagnostics and Intervention, Oncology, Umeå University, Umeå, SwedenDepartment of Public Health and Clinical Medicine, Umea University, Umea, SwedenDepartment of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå, SwedenNorthern Register Centre, Department of Public Health and Clinical Medicine, Umeå University, Umeå, SwedenObjective To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT).Design Retrospective analysis of serial cross-sectional screening study.Setting Population-based health examinations within primary care in Västerbotten County, Sweden.Participants Individuals aged 40- 50 and 60 years with participation from 1985 to 2017. Those with previously diagnosed diabetes and FPG≥7 mmol/L were excluded.Primary and secondary outcome measures Prevalence of hyperglycaemia on the OGTT (IGT and T2D defined as 2-hour postload capillary plasma glucose of 8.9–12.1 mmol/L and ≥12.2 mmol/L, respectively). Analyses were further stratified by age, sex and risk factor burden to identify groups at high or low risk of IGT and T2D on testing. The numbers needed to screen (NNS) to prevent one case of T2D through detection and treatment of IGT was estimated, combining prevalence numbers with average progression rates and intervention effects from previous meta-analyses.Results The prevalence of IGT ranged from 0.9% (95% CI 0.7% to 1.1%) to 29.6% (95% CI 27.4% to 31.7%), and the prevalence of T2D ranged from 0.06% (95% CI 0.02% to 0.11%) to 7.0% (95% CI 5.9% to 8.3%), depending strongly on age, sex and risk factor burden. The estimated NNS to prevent one case of T2D through detection and lifestyle treatment of IGT ranged from 1332 among 40-year-old men without risk factors, to 39 among 60-year-old women with all risk factors combined.Conclusions The prevalence of hyperglycaemia on OGTT is highly dependent on age, sex and risk factor burden; OGTT should be applied selectively to high-risk groups to avoid unnecessary testing in the general population.https://bmjopen.bmj.com/content/12/6/e062172.full |
| spellingShingle | Patrik Wennberg Mattias Brunström Anna Rosén Julia Otten Andreas Stomby Simon Vallin Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden BMJ Open |
| title | Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden |
| title_full | Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden |
| title_fullStr | Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden |
| title_full_unstemmed | Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden |
| title_short | Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden |
| title_sort | oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes population based cross sectional analyses of 146 000 health examinations in vasterbotten sweden |
| url | https://bmjopen.bmj.com/content/12/6/e062172.full |
| work_keys_str_mv | AT patrikwennberg oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden AT mattiasbrunstrom oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden AT annarosen oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden AT juliaotten oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden AT andreasstomby oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden AT simonvallin oralglucosetolerancetestingasacomplementtofastingplasmaglucoseinscreeningfortype2diabetespopulationbasedcrosssectionalanalysesof146000healthexaminationsinvasterbottensweden |